59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
3 citations
,
July 2025 in “Obesity Facts” GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
June 2026 in “Annals of Clinical Pathology” Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
June 2026 in “Skin Appendage Disorders” GLP-1 receptor agonists may increase the risk of hair loss, especially non-scarring types, due to weight loss-related nutrient deficiencies.